natgillin/translations-raw huggingface dataset:
The process according to claim 9, wherein at least 90% by weight of the particles obtained have a size lower than 350 µm, preferably lower than 300 µm, more preferably lower than 260 µm, more and more preferably lower than 200 µm. 
Postupak prema zahtjevu 9, naznačen time da barem 90% težinski dobivenih čestica ima veličinu manju od 350 ium, poželjno manju od 300 pum, još poželjnije manju od 260 um, a još više poželjnije manju od 200 um.
The combined preparation for use according to claim 20, which further comprises bisphosphonates or the pharmaceutical salts thereof. The combined preparation for use according to any of claims 20 or 21, where the composition is in a form adapted for intravenous administration. 
Kombinirani pripravak prema bilo kojem od zahtjeva 8 do 12, naznačen time što je pripravak u obliku prilagođenom za intravensku primjenu i koji dodatno sadrži natrij, klor, pufer i / ili druge pomoćne tvari, nosače i inhibitorne tvari odabrane od bisfosfonata ili pirofosfata
S-Vn-heteroaryl wherein n is 1, V is C1-C6 alkylene optionally substituted with C1-C6 alkyl, and heteroaryl is a 5-6 membered ring having 1-2 atoms independently selected from N, S and O; 
(ili) S-V,-heteroaril gdje n je 1, V je Ci-C4 alkilen po izboru supstituiran s C;-Cg alkil, i heteroaril je 5-6-eročlani prsten s 1-2 atoma nezavisno izabrana između N, S i O;
Use according to claim 12, wherein said fist type of transportation (202, 302) is an ocean going ship (202, 302) and said second type of transportation (204, 304) is a feeder barge (204, 304). 
Uporaba sukladno zahtjevu 12, pri čemu je prvi tip transporta (202, 302) prekooceanski brod (202, 302) a drugi tip transporta je (204, 304) Feeder teglenica (204, 304).
The solution obtained in this way can then be sterilized by filtration and subsequently dispensed into suitable containers such as vials or ampoules. 
Na ovaj način dobivena otopina se zatim može sterilizirati filtriranjem i neposredno zatim puniti u odgovarajuću ambalažu poput bočica ili ampula.
c') reducing the imine group using a reducing agent comprising a triacetoxyborohydride moiety to form an antigen-linker; reacting the antigen-linker with a carrier protein to form a conjugated antigen wherein the antigen is a bacterial capsular saccharide and wherein step a) comprises reacting the antigen with periodate. 
Cc") reduciranja iminske skupine reducensom koji sadrži triacetoksiborohidridni ostatak kako bi se dobio konjugat antigen-spojnica; d) reakcije kompleksa antigen-spojnica s proteinskim nosačem kako bi se dobio konjugirani antigen, gdje je antigen saharid iz bakterijske kapsule, te gdje se korak a) sastoji u reakciji antigena s perjodatom.
represents a benzene ring or a naphathalene; the ring being optionally substituted 1 to 4 substituents selected from a C1-3 alkyl group, a C1-2 perhalogenated alkyl group, a C3-4 cycloalkyl group, a C3-4 cydoalkyl-C1-3 alkyl group, a halogen atom, a hydroxyl group, a nitro, a cyano, an amino, a C1-3 alkoxy group optionally substituted by a C3-4 cycloalkyl group, a C1-2 perhalogenated alkoxy group or a C1-3 alkylsulfonyl group; and/or 
R2 predstavlja benzenski ili naftalenski prsten, gdje je navedeni prsten izborno supstituiran s 1 do 4 supstituenta, koje se bira između C,., alkilne skupine, Ci> perhalogenirane alkilne skupine, C3a cikloalkilne skupine, Ca cikloalkil-C;.3 alkilne skupine, atoma halogena, hidroksilne skupine, nitro, cijano, amino, Cia alkoksi skupine, izborno supstituirane s Caa cikloalkilnom skupinom, C,2 perhalogeniranom alkoksi skupinom ili C,3 alkilsulfonilnom skupinom; R3 predstavlja atom vodika ili atom halogena; R4 predstavlja atom vodika;
characterised in that the actuator mechanism (118) comprises a pivotally mounted lever, the input portion being arranged at an end of the lever and the pivotal mounting (126) being arranged between the input portion and an output portion of the lever. 
Brojač doze prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu se, u uporabi, osovina pobuđivača (120) pomiče uzdužno i s time povezana poluga (122) se vrti tako da se bočni razmak između pogona (124) i osi vrtnje povezane poluge (122) smanjuje.
Figure 12 shows the SDS concentration during diafiltration of the starting material. 
Slika 12 pokazuje koncentraciju SDS za vrijeme diafiltracije početnog materijala.
In some embodiments, an indicated daily dosage in the larger subject, including, but not limited to, humans, is in the range from about 0.5 mg to about 100 mg, conveniently administered in divided doses, including, but not limited to, up to four times a day or in extended release form. 
(li)u dozi od oko 0,5 mg do oko 100 mg spoja ili njegove farmaceutski prihvatljive soli ili solvata, koja se opcionalno primjenjuje u podijeljenim dozama do četiri puta dnevno ili u obliku s produženim oslobađanjem.
X is O, S or NH; and the dashed lines designated a and b each indicate an optional double bond, with the proviso that only a single double bond a or b exists in one compound; 
Xje0, Sili NH; i isprekidane linije, označene s a odnosno b, označuju izbornu dvostruku vezu, uz uvjet da u određenom spoju postoji samo jedna dvostruka veza, aili b; ili njegova farmaceutski prihvatljiva sol.
X-Ray Crystallographic Studies on Isomer B 
Kristalografsko proučavanje X-zrakama na Izomeru B
Calcineurin (PP-2B) Inhibitors / INS Expression Inhibitors such as cyclosporine A, Tacrolimus and ISA-247 from Isotechnika 
inhibitora kalcineurina (PP-2B) / inhibitora ekspresije INS-a kao što su ciklosporin A, takrolimus i ISA-247 od tvrtke Isotechnika;
Use of aminopyridine in the manufacture of a sustained release composition for improving walking of a patient with multiple sclerosis, said composition to be administered as a stable dose treatment twice daily in a therapeutic dose of 15 milligrams or less of aminopyridine. 
. Upotreba aminopridina u proizvodnji sastava s odgođenim oslobađanjem za tretiranje multiple skleroze, naznačena time da je sastav primijenjen dvaput dnevno u dozi od 10 miligrama ili manjoj, aminopiridina.
The process of paragraph 65, wherein said base is selected from the group consisting of organic, inorganic, and organometallic bases. 
Postupak u skladu s patentnim zahtjevom 55, naznačen time što navedenu bazu se bira iz skupine koju čine organske, anorganske i organometalne baze.
The mouse of claim 1, wherein the endogenous λ (lambda) light chain allele lacks an endogenous Vλ gene segment. 
Miš prema zahtjevu 1, naznačen time, što alelu endogenog lakog 2 (lambda) lanca nedostaje endogeni segment gena VA.
The pharmaceutical composition for use according to claim 5 or 6, comprising additional 5-HT7-active components selected from the group comprising aripiprazole, amisulpride, chlorpromazine, clozapine, risperidone, ziprasidone, fluoxetine, 5-CT, 5-methoxytryptamine, 8-OH-DPAT, aripiprazole, AS-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7, and Nw -methylserotonin. 
7. = Farmaceutski pripravak za uporabu prema zahtjevu 5 ili 6, naznačen time što sadrži dodatne 5-HT;. aktivne komponente odabrane iz skupine koja sadrži aripiprazol, amisulprid, klorpromazin, klozapin, risperidon, ziprasidon, fluoksetin, 5-CT, 5-metoksitriptamin, 8 -OH-DPAT, aripiprazol, A$S-19, E-55888, MSD-5a, LP-12, LP-44, LP-211, RA-7 i N*-metilserotonin.
The method according to claim 1, wherein the cartilage disorder is osteoarthritis. The method according to claim 1, wherein the cartilage disorder is cartilage injury. 
Spoj FGF-18 za uporabu prema bilo kojem od zahtjeva 1-9, naznačen time što je poremećaj hrskavice ozljeda hrskavice.
5). More particularly, the ridge portion 128 has a vertical dimension h, which is more than half of the smallest width w of the undercut groove 122, this smallest width w being measured as a perpendicular projection onto the bottom wall 124 of the longitudinal groove 122 . 
okomita dimenzija (h) navedenog dijela grebena (128), izmjerena u ravnini navedene bočne površine oštrice ključa, je više od polovice najmanje širine (w) navedenog podrezanog utora pored navedene bočne površine, navedena najmanja širina se mjeri kao okomita projekcija na navedenu unutarnju stjenku (124) navedenog uzdužnog utora.
for example describe that the following vitamins may be used in a cell culture medium: Biotin, Pantothenate, Choline Chloride, Folic Acid, Myo-Inositol, Niacinamide, Pyridoxine, Riboflavin, Vitamin B12, Thiamine, Putrescine. 
za primjer opisuju da slijedeći vitamini mogu biti korišteni u mediju za kulturu stanica: biotin, pantotenat, kolin klorid, folna kiselina, mioinozitol, niacinamid, piridoksin, riboflavin, vitamin BI2, tiamin, putrescin.
The method according to claim 10, characterized in that the group consisting of ammonium, nitrate and their respective aqueous complexes makes up at least 80 wt% of all solutes of the aqueous solution. 
Metoda prema zahtjevu 10, naznačena time da skupina koja se sastoji od amonijaka, nitrata i njihovih vodenih kompleksa čini najmanje 80% težinskog udjela svih otopljenih tvari u vodenoj otopini.
one to three paclitaxel molecules conjugated to said polypeptide, wherein said paclitaxel molecule(s) is conjugated to said Angiopep-2 as shown below: 
Konjugat prema zahtjevu 4, naznačen time da su navedene molekule Taxola konjugirane na navedeni polipeptid kako je prikazano ispod: Tazak
Such substances are e.g. lignite, brown coal, peat etc. 
Takove tvari su npr. lignit, smeđi ugljen, treset itd.
The device as claimed in claim 11, wherein the trigger lever has one of a cranked angled peripheral contour. 
poluga okidača (6.1, 6.2) ima koljenastu perifernu konturu ili perifernu konturu pod kutom.
The use according to claim 23, wherein the antibiotic resistant bacteria is resistant to vancomycin, methicillin, glycopeptide antibiotics, penicillin, or daptomycin. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što su bakterije otporne na antibiotike otporne na vankomicin, meticilin, glikopeptidne antibiotike, penicilin ili daptomicin.
A ddRNAi agent according to claim 5, wherein at least one of the other effector sequences is selected from SEQ ID NOS: 3, 9, 12, 13 and 23. 
Agens za ddRNKi prema patentnom zahtjevu 6, gdje najmanje jedna od drugih efektorskih sekvenci je sekvenca izabrana od sekvenci navedenih u SEQ ID NO: 1 do 8 ili 10 do 27.
is selected from the group consisting of H, and —CH3. 
je odabran od grupe koja se sastoji od H i -CH3; i
An ophthalmic or otorhinolaryngological device comprising the polymeric device material of claim 1 wherein the ophthalmic or otorhinolaryngological device is selected from the group consisting of intraocular lenses; contact lenses; keratoprostheses; corneal inlays or rings; otological ventilation tubes; and nasal implants. 
Oftalmički ili otorinolaringološki uređaj, naznačen time što sadrži polimerni materijal za navedeni uređaj u skladu s patentnim zahtjevom 1, gdje se oftalmički ili otorinolaringološki uređaj bira iz skupine koju čine intraokularno leće; kontaktne leće; keratoproteze; kornealni umetci ili prsteni; otološke cijevi za propuhivanje; te nazalni usatci.
The dosage regimen of any one of clauses 67-77, wherein a loading dosage amount of 600 mg to 1,600 mg is administered to the subject on day 1 and a dosage amount of 400 mg to 1,200 mg is administered to the subject for the rest of the treatment duration. 
Polimorfni oblik namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 16-22, naznačen time što se početnu količinu doze od 600 mg do 1600 mg primjenjuje na subjektu 1. dana, a količinu doze od 400 mg do 1200 mg se primjenjuje na subjektu tijekom ostatka trajanja liječenja.
A computer program comprising a plurality of instructions capable of execution by a computer system, that when so executed control the computer system to perform the method of any one of the preceding claims. 
Računalni program koji se sastoji od niza uputa koje računalni sustav može izvršiti, tako da kada se izvrše kontroliraju računalni sustav kako bi izvršio metodu prema bilo kojem od prethodnih zahtjeva.
The process of claim 3, wherein the water soluble species comprise charged species and neutral species and the ratio by weight of the total amount of charged species to the total amount of neutral species in the extraction solution is in a range selected from the group consisting of 20:100 to 90:100, 40:100 to 80:100, and 50:100 to 80:100. 
Proces iz patentnog zahtjeva 3, gdje u vodi topljive vrste sadrže naelektrizirane vrste i neutralne vrste i odnos po masi ukupne količine naelektriziranih vrsta prema ukupnoj količini neutralnih vrsta u ekstrakcijskoj otopini je u opsegu odabranom iz grupe koja se sastoji od 20:100 do 90:100, 40: 100 do 80:100, 1 50:100 do 80:100.
Method for taking a sample from a body cavity, such as cervical samples, comprising introduction of a sampler tube into the entrance of said cavity, moving the tube in said cavity up to contact with the blind end of the cavity and taking a sample by suctioning material at the end of said sampler tube through an opening thereof, characterised in that after inserting said sampler tube and before taking a sample a flushing solution is expelled from said sampler tube into said body cavity. 
Postupak za uzimanje uzorka, takvog uzorka kao što je uzorak iz grlića maternice, koji postupak obuhvaća uvođenje cijevi naprave za uzimanje uzorka u ulazni otvor navedene šupljine, pri čemu se ova cijev pomiče u navedenoj šupljini sve dok se ne dodirne sa zatvorenim krajem ove šupljine i uzimanje uzorka usisavanjem materijala na kraju navedene cijevi naprave za uzimanje uzorka kroz otvor koji se nalazi na njoj, naznačen time što se nakon uvođenja cijevi navedene naprave za uzimanje uzorka, a prije uzimanja uzorka, istisne otopina za ispiranje iz cijevi naprave za uzimanje uzorka u navedenu tjelesnu šupljinu.
drying the layer and cross-linking the polyvinyl alcohol and/or the polyvinyl alcohol copolymer with the aid of the cross-linking agent with formation of a barrier layer for hydrophobic compounds, wherein the cross-linking agent contributes to the formation of a three-dimensional network by reaction with said polyvinyl alcohol and/or said polyvinyl alcohol copolymer. 
sušenja sloja i umrežavanja polivinil-alkohola i/ili polivinil-alkoholnog kopolimera uz pomoć umrežujućeg sredstva, uz stvaranje izolirajućeg sloja (22a, 22b) za hidrofobne spojeve, gdje se supstrat (12) prije koraka a) i/ili nakon koraka c) oblaže najmanje jednim dodatnim vodenim pripravkom, gdje -
is a 3- to 10-membered ring or a 7- to 11-membered ring system, each ring or ring system containing ring members selected from carbon atoms and up to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 4 N, wherein up to 3 carbon atom ring members are independently selected from C(═O) and C(═S) and the sulfur atom ring members are independently selected from S(═O)u(═NR24)z, each ring or ring system optionally substituted with up to 5 substituents independently selected from R14; 
R je3- do 10-člani prsten ili 7- do 11-člani sustav prstena, pri čemu svaki prsten ili sustav prstena sadrži članove prstena koji su izabrani od atoma ugljika i do 4 heteroatoma nezavisno izabrana od maksimalno 2 O, maksimalno 2 S i maksimalno 4 N, gdje su maksimalno 3 atoma ugljika koji su članovi prstena nezavisno izabrani od C(=0) 1 C(=S) i članovi prstena atomi sumpora su nezavisno izabrani od S(=0),(SNR*),, pri čemu je svaki prsten ili sustav prstena izborno supstituiran sa do 5 supstituenata nezavisno izabrana od R'%
A compound according to any one of claims 1-13 or a pharmaceutically acceptable derivate thereof for use in the treatment of pain, a memory disorder, obesity, constipation, urinary incontinence, anxiety, cough, diarrhea, high blood pressure, epilepsy, anorexia/cachexia, or drug abuse in an animal, and wherein the pharmaceutically acceptable derivative is selected from the group consisting of pharmaceutically acceptable salt, solvate, radiolabeled, stereoisomer, enantiomer, diastereomer, other stereoisomeric form, racemic mixture, geometric isomer, and/or tautomer. 
Spoj prema bilo kojem zahtjevu od 1 do 19, naznačen time da je za upotrebu kao lijek. Spoj prema bilo kojem zahtjevu od 1 do 19, naznačen time da je za upotrebu u liječenju boli, poremećaja pamćenja, pretilosti, konstipacije, urinarne inkontinencije, anksioznosti, kašlja, dijareje, visokog krvnog tlaka, epilepsije, anoreksije/kaheksije, ili zloupotrebe droge kod životinja.
B is the B-chain of insulin lispro and has the amino acid sequence of SEQ ID NO: 3; and P is a PEG having a molecular weight in the range from about 20 kDa to about 40 kDa, and wherein A and B are properly cross-linked and P is attached via an urethane covalent bond to the epsilon-amino group of the lysine at position 28 ofB which comprises reacting the epsilon-amino group of the lysine at position 28 ofB with monomethoxypoly(ethylene glycol) p-nitrophenyl carbonate (mPEG-NPC) having a weight average molecular weight of between about 20 kDa and about 40 kDa in an aqueous solvent at a pH between about 8.5 and about 11.5 and at between about 25°C and about 30°C for a period of time between about 3 and about 6 hours. 
B je B-lanac inzulina lispro i ima aminokiselinski slijed SEQ ID NO: 3; i P je PEG čija je molekulska težina u rasponu od otprilike 20 kDa do otprilike 40 kDa, te gdje su A i B odgovarajuće umreženi, a P je vezan preko uretanske kovalentne veze na e-amino skupinu u lizinu na položaju 28 u B, naznačen time što se sastoji u reakciji e-amino skupine u lizinu na položaju 28 u B s monometoksipoli(etilen-glikol)p-nitrofenil-karbonatom (mPEG-NPC) s prosječnom molekulskom težinom između otprilike 20 kDa i otprilike 40 kDa, u vodenom otapalu, na pH između otprilike 8,5 i otprilike 11,5 i između otprilike 25 °C i otprilike 30 °C, u trajanju između otprilike 3 i otprilike 6 sata.
An immunogenic composition according to claim 1 wherein 19F capsular saccharide is conjugated to the carrier protein via a linker. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što je saharid iz kapsule 19F konjugiran s proteinskim nosačem preko spojnice.
In this way the dispenser can be set by the user in such a way that a desired dispensing pressure, for example for tapping beer under high pressure, with a large head, or under low pressure, with less frothing, can be set. 
Na ovaj način, korisnik može podesiti raspršivač na takav način da se može namjestiti željeni pritisak raspršivača, na primjer za istjecanje piva pod visokim tlakom, uz veliku glavu, ili pod niskim tlakom, uz manje pjenušanja.
In addition, replacing sugar by the sugar replacement composition in these applications has the advantage that no sugar is available for spoilage bacteria and moulds, but a selective energy source is present for the favourable microflora of the colon. 
Uz to, zamjena šećera u tim proizvodima sastavinom koja zamjenjuje šećer ima prednost što u tom slučaju nema šećera dostupnog za bakterije koje uzrokuju kvarenja i za plijesni, već se u proizvodu nalazi selektivni izvor energije za korisnu mikrofloru u debelom crijevu.
An affinity reagent according to claim 8, wherein the affinity reagent is a fully human or humanised antibody that is capable of inducing antibody-directed cell-mediated cytotoxicity (ADCC). 
Antitijelo za uporabu prema bilo kojem od patentnih zahtjeva 1-3 pri čemu je to antitijelo potpuno ljudsko ili humanizirano antitijelo koje je sposobno izazvati citotoksičnost posredovane stanicom usmjerenu antitijelom (ADCC)
26A) inhibition of spheroid growth in AdrR cells, (FIG. 
(vi) inhibicija migracije stanica koje eksprimiraju ErbB3;
Particular examples of the compounds of Formula I are compounds of Formula IA: 
Konkretni primjeri spojeva prikazanih Formulom I su spojevi prikazani Formulom TA: m
A composition for use in treating or controlling post-operative ocular inflammation of the anterior segment of an eye, said inflammation resulting from a procedure selected from the group consisting of photorefractive keratectomy, cataract removal surgery, intraocular lens ("IOL") implantation, laser-assisted in situ keratomileusis ("LASIK"), conductive keratoplasty, and radial keratotomy; said composition comprising a dissociated glucocorticoid receptor agonist ("DIGRA"), or a pharmaceutically acceptable salt thereof; wherein the DIGRA comprises a compound having Formula I wherein A comprises a dihydrobenzofuranyl group substituted with a halogen atom; Q comprises a quinolinyl or isoquinolinyl group substituted with a C1-C10 alkyl group; R1 and R2 are independently selected from the group consisting of unsubstituted and substituted C1-C5 alkyl groups; B is a C1-C3 alkylene group; D is the -NH- group; E is the hydroxy group; and R3 comprises a completely halogenated C1-C10 alkyl group. 
HR P20130631 T1 PATENTNI ZAHTJEVI Pripravak za uporabu u liječenju ili kontroli post-operativne očne upale prednjeg segmenta oka, pri čemu je spomenuta upala rezultat procedure izabrane iz skupine koja se sastoji od fotorefraktivne keratektomije, operacije uklanjanja katarakta, umetanja intraokularnih leća (,IOL"), in situ keratomileuze potpomognute laserom (»LASIK*), konduktivne keratoplastije, te radijalne keratotomije; pri čemu spomenuti pripravak sadrži disocirani agonist glukokortikoid receptora (,,DIGRA"), ili njegovu farmaceutski prihvatljivu sol; pri čemu DIGRA sadrži spoj formule I.
In some further embodiments, the pharmaceutical composition is suitable for oral administration to a human. 
Farmaceutska kompozicija iz patentnog zahtjeva 9, pri čemu je spomenuta kompozicija: (i) pogodna za oralnu administraciju kod ljudi;
System (1) according to claim 1, characterized in that said cooled support means (7) is equipped with: 
Sustav (1) sukladno patentnom zahtjevu 1, naznačen time što navedena hlađena potporna jedinica (7) sadrži:
When the mobile station apparatus performs the information-keeping type of mapping, the base station apparatus can transmit, to the mobile station apparatus, the RRC signaling including information indicating a certain amount (keeping value, hereinafter) of resources in which the reception quality information can be mapped. 
Uređaj mobilne stanice (200) prema zahtjevu 3, naznačen time da uređaj mobilne stanice dodatno ima sredstva za prijem, od uređaja bazne stanice (100), RRC signalizacije koja sadrži informacije koje ukazuju na unaprijed definiranu količinu resursa u kojima se mogu mapirati informacije o kvaliteti prijema.
is chosen from the series consisting of (C1-C7)-alkyl, (C3-C7)-cycloalkyl-CsH2s— and Ar—CsH2s—, wherein s is an integer chosen from the series consisting of 0, 1, 2 and 3; 
R? se bira iz skupine koju čine (C,-Cy)-alkil, (C3-C;)-cikloalkil-C,H>, i Ar-C,H>,-, gdje je s cijeli broj, kojeg se bira iz skupine koju čine 0, 1,213;
More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu se primjenjuje oralnim putem.
The blister pack according to Claim 8, in which said top layer (6) comprises at least other two layers (6B, 6C) located on apposite sides of said aluminium layer (6A). 
. Blister pakiranje prema 8., naznačeno time da navedeni gornji sloj (6) sadrži najmanje još dva sloja (6p, 6c) koji se nalaze na suprotnim stranama navedenog aluminijskog sloja (6).